Market Overview

Sarepta Therapeutics Dropped 10% Following FDA News


Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 10 percent on Monday and hit a new 52-week low of $10.60 after the company received a notification from the U.S. Food and Drug Administration.

The FDA told Sarepta Therapeutics that it requires additional time to complete its review of the company's New Drug Application (NDA) for etelirsen, for the treatment of Duchenne muscular dystrophy.

Sarepta Therapeutics noted that the Prescription Drug User Fee Act (PDUFA) date for eteplirsen has been extended to May 26, 2016.

Eteplirsen has already been granted Priority Review status which is designated for drugs that provide a treatment where no other adequate therapy exists.

"While our primary goal is to bring treatment to patients with Duchenne as quickly as possible, we appreciate the efforts of the FDA to conduct a complete review of all of the data supporting our NDA and we remain committed to working closely with them throughout the remainder of the regulatory process", said Edward Kaye, Sarepta's interim chief executive officer and chief medical officer.

Posted-In: DMD Duchenne Muscular Dystrophy Edward Kaye eteplirsen New Drug ApplicationNews FDA Movers


Related Articles (SRPT)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Outerwall Gains 7% As Activist Investor Discloses 14% Stake

New Report Reaffirms What Apple's Next Growth Engine Could Be